The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 22, 2021

Filed:

May. 23, 2017
Applicants:

Bayer Pharma Aktiengesellschaft, Berlin, DE;

Deutsches Krebsforschungszentrum (Dkfz), Heidelberg, DE;

Inventors:

Norbert Schmees, Berlin, DE;

Ilona Gutcher, Berlin, DE;

Horst Irlbacher, Berlin, DE;

Benjamin Bader, Berlin, DE;

Na Zhao, Beijng, CN;

Michael Platten, Heidelberg, DE;

Ulrike Röhn, Berlin, DE;

Ludwig Zorn, Berlin, DE;

Lars Röse, Berlin, DE;

Detlef Stöckigt, Potsdam, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 237/14 (2006.01); C07D 237/20 (2006.01); C07D 401/10 (2006.01); C07D 405/12 (2006.01); A61K 31/501 (2006.01); A61P 35/00 (2006.01); A61K 31/50 (2006.01); A61K 45/06 (2006.01); C07D 237/24 (2006.01); C07D 403/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/501 (2013.01); A61K 31/50 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 237/24 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01);
Abstract

The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.


Find Patent Forward Citations

Loading…